Nearshore Protein: High-throughput wet-lab and data package services empowering AI are still in the early stages of market expansion.

Nearby Protein has issued an announcement on severe abnormal fluctuations in stock trading and a risk warning. In 2025, the company's revenue from products related to RNA vaccine drugs accounted for 11.38% of total product revenue, a relatively low proportion. The company's AI-enabled high-throughput wet-lab and data package services are still in the early stage of market expansion. As of the first half of 2026, revenue from related businesses accounted for less than 2% of the company's overall operating revenue. Given that the application of AI in the pharmaceutical R&D industry is still in its infancy, there are risks such as rapid technological iteration, long industry validation cycles, and significant difficulty in commercialization. There is substantial uncertainty regarding the realization of the company's future related revenue and profitability.